Fig. 4.

Mitigation of established colitis by NCK2025. (A–D) Three groups of C57BL/6 mice (10 per group) first received a 5-d cycle of 3% DSS dissolved in sterile water to initiate colitis, and two of the groups were subsequently treated orally with NCK56 or NCK2025 for 4 consecutive d. Disease progression was monitored to day 13 of the protocol when mice were killed, and colons were assessed. FOB, fecal hemoccult blood positivity; DAI, disease activity index. (B–D) Colonic H&E staining. (B) DSS-treated mice. (C) DSS-NCK56–treated mice. (D) DSS-NCK025–treated mice. (E) Colitis score. Data are representative of at least three independent experiments. (F) Colonic cytokine analysis. Colons of each group of mice were washed, cut into pieces, and cultured for 18 h at 37 °C. Cytokines were assayed by ELISA.